Clinical Trial Update: Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase [Phase 2]

View source ↗

Summary

A Phase 2 trial of STI571 (imatinib) for Ph+ chronic myeloid leukemia in accelerated and blastic phase has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: University of Bologna | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED